Results: Of the 107,939 patients with cirrhosis (1742 cured HCV, 23,292 ALD, 66,314 MASLD), 52.8% (n=56,940) died during a median follow up of 1.8 years

Safety and Precautions Side Effect Profile Based on available research, 5-Amino-1MQ appears to have a favorable safety profile: Rodent studies have found no significant adverse effects No established human toxicity profile is currently available The most commonly reported effect is potential sleep disturbance An acclimation period may be necessary, with some subjects reporting decreased exercise tolerance with cardiovascular exercise during initial treatment Special Populations and Contraindications Due to limited safety data, the following populations should exercise caution or avoid use until more research is available: Pregnant or breastfeeding individuals Those with chronic health conditions Individuals taking medications that might interact with 5-Amino-1MQ Takeaway 5-Amino-1MQ represents a promising approach for addressing metabolic disorders through NNMT inhibition
221,222 Under physiological conditions, microglia can play a neuroprotective role by producing cytokines
Funding The research received funding from the Zhejiang Provincial Natural Science Foundation in China (Grant No.LY23H110001)